BiondVax to Present at BIO-Europe Spring
16 Marzo 2023 - 11:10AM
via InvestorWire
– BiondVax
Pharmaceuticals Ltd. (Nasdaq: BVXV), a
biopharmaceutical company focused on developing, manufacturing and
commercializing innovative immunotherapeutic products primarily for
the treatment of infectious and autoimmune diseases, announces
today that its CEO Amir Reichman will be presenting in-person at
the 17th annual BIO-Europe Spring taking place March 20–22, 2023,
in Basel, Switzerland. The event is expected to bring together over
2,800 executives from biotech, pharma and finance companies to
engage in 15,000+ one-to-one meetings.
Presentation Details:
- Date: Tuesday, March 21, 2023
- Time: 11:30 a.m.
- Location: Messe Basel, North Entrance, Exhibit Hall Stage
Reichman’s presentation will focus on recent
successful preclinical in vivo results of BiondVax’s innovative
inhaled COVID-19 treatment and additional pipeline plans, including
nanosized VHH-antibodies (NanoAbs) for the treatment of autoimmune
diseases such as psoriasis, asthma, psoriatic arthritis and macular
degeneration. BiondVax’s de-risked R&D strategy includes
generating a pipeline of bio-better NanoAbs aimed at molecular
targets validated by currently approved monoclonal antibodies
(mAbs) addressing diseases with underserved medical needs and
attractive commercial opportunities.
Reichman and Joshua Phillipson, Director of
Investor Relations and Communications, will be available to meet
potential partners, collaborators, and investors. To schedule a
meeting with BiondVax register now at
https://informaconnect.com/bioeurope-spring/. Alternatively, reach
out to the Company directly at the contact information below.
About BiondVaxBiondVax
Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company
focused on developing, manufacturing, and commercializing
innovative immunotherapeutic products primarily for the treatment
of infectious and autoimmune diseases. Since its inception,
BiondVax has executed eight clinical trials including a
seven-country, 12,400-participant Phase 3 trial of its prior
vaccine candidate and has built a state-of-the-art manufacturing
facility for biopharmaceutical products. With highly experienced
pharmaceutical industry leadership, BiondVax is aiming to develop a
pipeline of diversified and commercially viable products and
platforms beginning with an innovative nanosized antibody (NanoAb)
pipeline. www.biondvax.com.
Contact DetailsJoshua E Phillipson | +972 8 930
2529 | j.phillipson@biondvax.com
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Litigation Reform Act
of 1995. Words such as “expect,” “believe,” “intend,” “plan,”
“continue,” “may,” “will,” “anticipate,” and similar expressions
are intended to identify forward-looking statements. All
statements, other than statements of historical facts, included in
this communication regarding strategy, future operations, future
financings, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, acquiring an additional license from Max
Planck for the therapeutic and commercial potential of nanosized
antibodies (NanoAbs); and the timing of NanoAb proof-of-concept
studies and clinical trials and the necessary steps needed for such
studies and trials. These forward-looking statements reflect
management’s current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from
those expected by the management of BiondVax Pharmaceuticals Ltd.
Risks and uncertainties include, but are not limited to, the risk
that we may not obtain a second NanoAb license from Max Planck for
a NanoAb targeting IL-17 as a treatment for psoriasis, the risk of
a delay in proof-of-concept studies and the commencement of
clinical trials for NanoAbs, if any, and delays in the necessary
steps needed for such studies and trials; the risk that the
therapeutic and commercial potential of NanoAbs will not be met;
the risk that clinical trials relating to NanoAbs will fail in
whole or in part; the risk that BiondVax may not be able to secure
additional capital on attractive terms, if at all; risks relating
to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to
acquire rights to additional product opportunities; BiondVax’s
ability to enter into collaborations on terms acceptable to
BiondVax or at all; timing of receipt of regulatory approval of
BiondVax’s manufacturing facility in Jerusalem, if at all or when
required; the risk that the manufacturing facility will not be able
to be used for a wide variety of applications and other vaccine and
treatment technologies, and the risk that drug development involves
a lengthy and expensive process with uncertain outcomes. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading “Risk Factors” in the
Company's Annual Report on Form 20-F filed with the Securities and
Exchange Commission on March 28, 2022. BiondVax undertakes no
obligation to revise or update any forward-looking statement for
any reason.
Corporate Communications: InvestorBrandNetwork
(IBN) Los Angeles, Californiawww.InvestorBrandNetwork.com
310.299.1717 OfficeEditor@InvestorBrandNetwork.com
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Gráfica de Acción Histórica
De May 2023 a May 2024